HYDROXYCARBAMINE: FROM AN OLD DRUG USED IN MALIGNANT HEMOPATHIES TO A CURRENT STANDARD IN SICKLE CELL DISEASE

HYDROXYCARBAMINE: FROM AN OLD DRUG USED IN MALIGNANT HEMOPATHIES TO A CURRENT STANDARD IN SICKLE CELL DISEASE

While hydroxycarbamine (hydroxyurea, HU) has less and less indications in malignant hemopathies, it represents the only widely used drug which modifies sickle cell disease pathogenesis. Clinical experience with HU for patients with sickle cell disease has been accumulated over the past 25 years in W...

Full description

Bibliographic Details
Main Authors: Giovanna Cannas, Solene Poutrel, Xavier Thomas
Format: Article
Language:English
Published: PAGEPress Publications 2017-02-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
hydroxyurea
treatment
sickle cell anemia
clinical management
hemoglobinopathies
prognosis.
Online Access:http://www.mjhid.org/index.php/mjhid/article/view/2820

Similar Items

Similar Items